加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.5051
−US$0.0999 · -16.51%
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
前收盘价
US$0.5051
−US$0.0999 · -16.51%
盘前
US$0.505
−US$0.0001 · -0.02%
10月13日 4:19 ET
盘中时间采用ET。市场数据可能有所延迟。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日内区间
当前US$0.5051
52周区间
当前US$0.5051
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
51
合理估值
情绪
69
看涨
风险
45
风险偏高
动量
69
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
日内区间
当前US$0.5051
52周区间
当前US$0.5051
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.46亿 USD | 1.45亿 USD | 1.46亿 USD | 1.57亿 USD | 2.1亿 USD |
| 销货成本 | 594.9万 USD | 600.7万 USD | 494.2万 USD | 521.3万 USD | 340.2万 USD |
| 毛利 | 1.4亿 USD | 1.39亿 USD | 1.41亿 USD | 1.52亿 USD | 2.06亿 USD |
| 研究与开发 | 1.26亿 USD | 1.43亿 USD | 1.39亿 USD | 1.49亿 USD | 1.61亿 USD |
| 销售、一般及管理费用 | 1.05亿 USD | 1.15亿 USD | 1.32亿 USD | 1.45亿 USD | 1.44亿 USD |
| 营业费用 | 2.31亿 USD | 2.59亿 USD | 2.71亿 USD | 2.94亿 USD | 3.05亿 USD |
| 利息收入 | 277.3万 USD | 740万 USD | 1094.3万 USD | 235.9万 USD | 58.2万 USD |
| 利息支出 | 4584.9万 USD | 3742.2万 USD | 2382.3万 USD | 2499.6万 USD | 2604.6万 USD |
| 折旧和摊销 | 29.6万 USD | 34万 USD | 53万 USD | 62.1万 USD | 78.9万 USD |
| 营业利润 | −9070.7万 USD | −1.19亿 USD | −1.3亿 USD | −1.42亿 USD | −9827.1万 USD |
| 净利润 | −1.96亿 USD | −7642.2万 USD | −1.43亿 USD | −1.65亿 USD | −1.24亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.50
上涨空间 1780.82%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年2月26日 | 1:15 | — | — |
已生效 2025年2月26日
1:15
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI139.61万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF54.2万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 ETFIWM30.07万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Russell 2000 ETFVTWO23.44万0.00%180亿 USD0.06%US$112.27-0.35%
Fidelity Enhanced Small Cap ETFFESM11.08万—64.1亿 USD0.28%US$45.24-0.48%
iShares Micro-Cap ETFIWC3.84万0.00%13.17亿 USD0.60%US$181.66-0.73%
Invesco NASDAQ Future Gen 200 ETFQQQS3.5万0.15%2275.83万 USD0.20%US$41.414-1.73%
Vanguard Russell 2000 Value ETFVTWV3.24万0.00%14亿 USD0.06%US$185.97+0.08%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSVanguard Russell 2000 Value ETFVTWVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
